TFRC and cancer: In addition to this, we demonstrate that a blockade of the V-ATPase pathway in cancer cells promotes the expression of a cancer therapeutic target, CD71 (45), and thus can be used in combination with anti-CD71 antibodies to induce a “synthetic” PrCR.